Back to results
US 12,128,098 B2Granted
Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
AssigneeSquarex, LLC
InventorHugh McTavish
Life of this patent
Estimating the term…
Abstract
A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.
Claims19
A method of treating herpes simplex virus (HSV) infection comprising:
- an administering step comprising:
- applying a topical immunosensitizer to the skin of a person infected with HSV at a time when the person is not having an HSV outbreak, or applying a topical immunosensitizer to the skin of a person infected with HSV during an HSV outbreak wherein the applying is at a site other than a site of an HSV lesion;
- wherein the method does not further comprise (i) applying a topical immunosensitizer to the skin of a person infected with HSV on an HSV lesion at a time of an HSV outbreak in the person;
- or (ii) intradermally injecting a recall antigen into a person infected with HSV in an HSV lesion at the time of an HSV outbreak in the person;
- wherein the topical immunosensitizer comprises a squaric acid ester, diphenylcyclopropenone (DPCP), 1-chloro-2,4-dinitrobenzene (DNCB), or 1-chloro-2,6-dinitrobenzene;
- wherein the method reduces the frequency of HSV outbreaks in the person after the administering step;
- wherein the person has had HSV outbreaks before the administering step and is in recognized need of treatment for HSV infection;
- wherein the person has genital herpes.
5 more elements
A method of treating herpes simple virus (HSV) infection comprising:
- an administering step comprising:
- applying a topical immunosensitizer to the skin of a person infected with HSV at a site other than the genitals or lips, or to the genitals or the lips but at a time when the person is not having an HSV outbreak on the genitals or lips;
- wherein the method does not further comprise (i) applying a topical immunosensitizer to the skin of a person infected with HSV on an HSV lesion at a time of an HSV outbreak in the person;
- or (ii) intradermally injecting a recall antigen into a person infected with HSV in an HSV lesion at the time of an HSV outbreak in the person;
- wherein the topical immunosensitizer comprises a squaric acid ester, diphenylcyclopropenone (DPCP), 1-chloro-2,4-dinitrobenzene (DNCB), or 1-chloro-2,6-dinitrobenzene;
- wherein the method reduces the frequency—of HSV outbreaks in the person after the administering step;
- wherein the person has had HSV outbreaks before the administering step and is in recognized need of treatment for HSV infection;
- wherein the person has genital herpes.
5 more elements
Dependencies are inferred from the claim text.